Recommended

FDA tightens COVID vaccine use
Decentralised manufacturing consortium launched
Trial boost for myasthenia gravis drug
FDA starts publishing daily AE data
WEBINAR | The Future of Sterility Testing: One-Day Results with Advanced RT-rt PCR Technology | 5 NOV
WEBINAR | Mastering Impurity Profiling: USP’s Evolving Standards and Strategies | 15 OCT
news

Construction starts on $400m biosimilars production centre in Slovenia

2
SHARES

Lek Pharmaceuticals, part of Sandoz, has started building a $400 million biologics manufacturing centre in Slovenia.

Construction starts on $400m biosimilars production centre in Slovenia

The first stage of construction has officially begun on Lek Pharmaceuticals’ new biologics and biosimilars production centre in Lendava, north eastern Slovenia.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

Representing the largest foreign direct investment in Slovenia, the launch of the $400 million centre was attended by key Slovenian representatives, including the Prime Minister, Robert Golob.

Sandoz announced plans for the facility in March 2023.

Once completed, the 40,000-square-metre centre will be used to produce active pharmaceutical ingredients (API) for biosimilars in Sandoz’s rheumatology, oncology and immunology portfolio. Sandoz is the parent company of Lek Pharmaceuticals, the oldest pharmaceutical company in Slovenia.

“Our new Production Center for Biosimilars in Lendava will further bolster our manufacturing capabilities and support our ambition to drive the future growth of our global biosimilar portfolio,” commented Richard Saynor, Sandoz’s CEO.

Sandoz also aims for the site to become “Europe’s most efficient production of active pharmaceutical ingredients for biologics,” a statement said.

Sandoz mobilises critical medicine production in Europe

Significance of the biosimilars centre in Lendava

The first of three facilities to be built at the site will generate energy for the existing operations and will meet the needs of the future centre for API production. The new biosimilars production centre will also include facilities for manufacturing and storage.

The centre, which will create up to 330 new jobs in the region, is expected to be operational by the end of 2026.

Commenting on the wider significance of the investment, Slovenian, Prime Minister Dr Robert Golob stated: “In the field of biopharmaceuticals, we have already succeeded in becoming a ‘little Switzerland’ in Slovenia. By investing in science and development, we enable similar ‘little Switzerlands’ to happen in other areas as well.”

The existing site in Lendava currently hosts two facilities: Anti-infectives Lendava, which produces the active ingredient of Sandoz’s best-selling broad-spectrum antibiotic and Solids Lendava, the largest solid pharmaceutical packaging plant in Sandoz. The site employs 775 people full time, Sandoz said.

Share via
Share via